Human Growth Hormone - Research News and Information

Saturday, January 10, 2009

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

2 Nov 2008 BACKGROUND: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of ... Read more...

Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary.

29 Sep 2008 SNAP-25, a synaptosome-associated exocytosis protein of 25 kd mw, plays an important role in the secretory activity of several endocrine cells. In the present study, we investigated surgically removed pituitary adenomas including 40 prolactin ... Read more...

Analysis of Cibacron blue F3G-A interaction with therapeutic proteins by MALDI-TOF mass spectrometry.

30 Aug 2008 The formation of the complexes between Cibacron blue F3G-A and two therapeutic proteins, recombinant human interferon-alpha2b and recombinant human growth hormone, was investigated. The method of time-resolved limited proteolysis coupled with ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Human Growth Hormone'

These are the very latest articles for this heading:

• Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. 2 Nov 2008
• Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. 2 Nov 2008
• Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. 2 Nov 2008
• Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary. 29 Sep 2008
• Analysis of Cibacron blue F3G-A interaction with therapeutic proteins by MALDI-TOF mass spectrometry. 30 Aug 2008
• Growth hormone treatment in short children with chronic kidney disease. 30 Aug 2008
• The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. 30 Aug 2008
• Growth hormone responsiveness: peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS): data from the National Cooperative Growth Study. 30 Aug 2008
• Treatment approaches for growth failure. 30 Aug 2008
• Treatment approaches for growth failure. 30 Aug 2008
• The next generation of human growth hormone. How Serostim and tesamorelin measure up. 30 Aug 2008
• [The danger of small height. Does a lower height become pathological in our society?] 19 Aug 2008
• Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. 13 Aug 2008
• Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. 4 Aug 2008
• Adult-onset growth hormone deficiency: causes, complications and treatment options. 30 Jul 2008
• Safety and efficacy of growth hormone treatment in small for gestational age children. 30 Jul 2008
• Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. 30 Jul 2008
• Medicine and science in the fight against doping in sport. 30 Jul 2008
• Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. 30 Jul 2008
• Growth hormone in cystic fibrosis. 30 Jul 2008

See a longer list of these articles.

Technical information about 'Human Growth Hormone'

Definition: A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.

Chemical name: Somatotropin (human)

Registry Number: 12629-01-5

Descriptor UI: D019382

Alternative terms: Human Growth Hormone; Growth Hormone, Human; Somatotropin (Human); Somatropin (Human); hGH (Human Growth Hormone); Somatropin; Genotropin; Pharmacia Brand of Human Growth Hormone; Pharmacia Spain Brand of Human Growth Hormone; Genotonorm; Humatrope; Umatrope; Lilly Brand of Human Growth Hormone; Eli Lilly Brand of Human Growth Hormone; Irisfarma Brand of Human Growth Hormone; Maxomat; Sanofi Synthelabo Brand of Human Growth Hormone; Norditropin; Pisa Brand of Human Growth Hormone; Novo Nordisk Brand of Human Growth Hormone; Norditropin Simplexx; Norditropine; Zomacton; Ferring Brand of Human Growth Hormone; Omnitrope; Sandoz Brand of Human Growth Hormone; Recombinant Human Growth Hormone (Mammalian); r-hGH-M; r-hGH(m); Saizen; Allphar Brand of Human Growth Hormone; Serostim; Serono Brand of Human Growth Hormone; Cryo-Tropin; Cryo Tropin; CryoTropin; Cryopharma Brand of Human Growth Hormone; Nutropin; Hoffmann La-Roche Brand of Human Growth Hormone; Hoffmann La Roche Brand of Human Growth Hormone;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D06.472.699.631.525.425.875; D12.644.548.691.525.425.875;

History Note: 2003 (1997); for SEROSTIM use SOMATOTROPINS, RECOMBINANT (NM) 1996-2002; use NORDITROPIN (NM) 1992-1996

Technical Notes: GROWTH HORMONE, unspecified is also available; despite entry term, coordinate with RECOMBINANT PROTEINS for recombinant human growth hormone